Pomalidomide

BNF:
8.2.4
Status:
Do Not Prescribe (DNP), Red
Decision Date:
February 2017
 

Comments

RED:1,2,3 NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib.

DO NOT PRESCRIBE (DNP)6: NICE TA602: Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma. (Terminated appraisal, decision date - Oct 2019)

Black Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again